Article
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
American journal of obstetrics and gynecology - 1 Jul 2021
Schrijver Lieske H, Antoniou Antonis C, Olsson Håkan, Mooij Thea M, Roos-Blom Marie-José, Azarang Leyla, Adlard Julian, Ahmed Munaza, Barrowdale Daniel, Davidson Rosemarie, Donaldson Alan, Eeles Ros, Evans D Gareth, Frost Debra, Henderson Alex, Izatt Louise, Ong Kai-Ren, Bonadona Valérie, Coupier Isabelle, Faivre Laurence, Fricker Jean-Pierre, Gesta Paul, van Engelen Klaartje, Jager Agnes, Menko Fred H, Mourits Marian J E, Singer Christian F, Tan Yen Y, Foretova Lenka, Navratilova Marie, Schmutzler Rita K, Ellberg Carolina, Gerdes Anne-Marie, Caldes Trinidad, Simard Jacques, Olah Edith, Jakubowska Anna, Rantala Johanna, Osorio Ana, Hopper John L, Phillips Kelly-Anne, Milne Roger L, Beth Terry Mary, Noguès Catherine, Engel Christoph, Kast Karin, Goldgar David E, van Leeuwen Flora E, Easton Douglas F, Andrieu Nadine, Rookus Matti A
Abstract excerpt
BACKGROUND: Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive use. Although the effects of using oral contraceptives in the general population are well established (approximately 50% risk reduction in ovarian cancer), the estimated risk reduction in mutation carriers is much less precise because of potential bias and small sample sizes....
Read the complete abstract on PubMed